Cardiovascular Diseases Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD
Verified date | December 2022 |
Source | Akcea Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.
Status | Completed |
Enrollment | 114 |
Est. completion date | February 25, 2020 |
Est. primary completion date | November 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Key Inclusion Criteria: - Clinical diagnosis of CVD (defined as documented coronary artery disease, stroke, or peripheral artery disease). - Fasting serum triglycerides (TG) greater than or equal to (=) 200 milligrams per deciliter (mg/dL) (= 2.3 millimoles per liter (mmol/L)) and less than or equal to (=) 500 mg/dL (= 5.7 mmol/L) at Screening. - Fasting TG = 200 mg/dL and = 500 mg/dL at Qualification visit. - Must be on standard-of-care preventative therapy for known CVD risk factors. Key Exclusion Criteria: - Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/transient ischemic attack (TIA). - Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis. - Heart failure New York Heart Association (NYHA) class IV. - Type 1 diabetes mellitus. - Type 2 diabetes mellitus with any of the following: - Newly diagnosed within 12 weeks of Screening. - Glycated hemoglobin (HbA1c) = 9.0% at Screening. - Recent change in anti-diabetic pharmacotherapy (change in dosage or addition of new medication within 12 weeks of Screening [with the exception of ± 10 units of insulin]. - Body Mass Index (BMI) greater than (>) 40 kilograms per square meter (kg/m^2). |
Country | Name | City | State |
---|---|---|---|
Canada | Clinical Site | Brossard | Quebec |
Canada | Clinical Site | Cambridge | Ontario |
Canada | Clinical Site | Chicoutimi | Quebec |
Canada | Clinical Site | Gatineau | Quebec |
Canada | Clinical Site | Montréal | Quebec |
Canada | Clinical Site | Québec | Quebec |
Canada | Clinical Site | Sudbury | Ontario |
United States | Clinical Site | Ames | Iowa |
United States | Clinical Site | Boca Raton | Florida |
United States | Clinical Site | Carmichael | California |
United States | Clinical Site | Cooperstown | New York |
United States | Clinical Site | Cottonwood | Arizona |
United States | Clinical Site | Fall River | Massachusetts |
United States | Clinical Site | Fresno | California |
United States | Clinical Site | Greer | South Carolina |
United States | Clinical Site | High Point | North Carolina |
United States | Clinical Site | Houston | Texas |
United States | Clinical Site | Jacksonville | Florida |
United States | Clinical Site | Kansas City | Kansas |
United States | Clinical Site | La Jolla | California |
United States | Clinical Site | Lansdale | Pennsylvania |
United States | Clinical Site | Little Rock | Arkansas |
United States | Clinical Site | Long Beach | California |
United States | Clinical Site | Louisville | Kentucky |
United States | Clinical Site | Milwaukee | Wisconsin |
United States | Clinical Site | Montclair | California |
United States | Clinical Site | Munster | Indiana |
United States | Clinical Site | New Port Richey | Florida |
United States | Clinical Site | Portland | Oregon |
United States | Clinical Site | Providence | Rhode Island |
United States | Clinical Site | Wilmington | Delaware |
Lead Sponsor | Collaborator |
---|---|
Akcea Therapeutics | Ionis Pharmaceuticals, Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | An analysis of covariance (ANCOVA) model was performed on the log ratio of TG value at the Primary Analysis Time Point to TG value at Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: (ratio of TG value at the Primary Analysis Time Point to TG value at Baseline - 1) × 100. | Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D) | |
Primary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. A TEAE was defined as any AE starting on or after the first dose of the study drug. | Up to the 13-week post-treatment follow-up period (Up to approximately 15 months) | |
Secondary | Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | An ANCOVA model was performed on the log ratio of Primary Analysis Time Point value to Baseline value for ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I. The estimate of the log ratio was converted back to the original scale and percent change for each lipid parameter was calculated using formula: (ratio of Primary Analysis Time Point value to Baseline value - 1) × 100. | Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D) | |
Secondary | Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 150 mg/dL (<= 1.7 Millimoles Per Liter [mmol/L]) | The percentage of participants who achieved <= 150 mg/dL or <= 1.7 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate. | Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D) | |
Secondary | Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 100 mg/dL (<= 1.13 mmol/L) | The percentage of participants who achieved <= 100 mg/dL or <= 1.13 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate. | Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D) | |
Secondary | Maximum Plasma Concentration (Cmax) of ISIS 678354 | Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) | ||
Secondary | Time to Reach Maximum Plasma Concentration (Tmax) of ISIS 678354 | Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) | ||
Secondary | Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours (AUC0-24) of ISIS 678354 | Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|